Nucleotide excision repair gene variants and association with survival in osteosarcoma patients treated with neoadjuvant chemotherapy.
about
Predictive Value of Ercc1 and Xpd Polymorphisms for Clinical Outcomes of Patients Receiving Neoadjuvant Therapy: A Prisma-Compliant Meta-AnalysisAssociation between the XPG Asp1104His and XPF Arg415Gln polymorphisms and risk of cancer: a meta-analysisAssociation between the ERCC5 Asp1104His polymorphism and cancer risk: a meta-analysis.Potentially functional variants in the core nucleotide excision repair genes predict survival in Japanese gastric cancer patients.The associations between immunity-related genes and breast cancer prognosis in Korean women.Association of xeroderma pigmentosum complementation group G Asp1104His polymorphism with breast cancer risk: A cumulative meta-analysis.ERCC1 and ERCC2 variants predict survival in gastric cancer patients.Translesion polymerase genes polymorphisms and haplotypes influence survival of osteosarcoma patients.Genetic variability of DNA repair mechanisms influences chemotherapy outcome of gastric cancer.Genetic polymorphisms in nucleotide excision repair pathway influences response to chemotherapy and overall survival in osteosarcoma.Homologous Recombination Repair Polymorphisms and the Risk for Osteosarcoma.The association of XPG and MMS19L polymorphisms response to chemotherapy in osteosarcoma.Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma.Molecular mechanisms of chemoresistance in osteosarcoma (Review).Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy?Research progress on the multidrug resistance mechanisms of osteosarcoma chemotherapy and reversal.ERCC polymorphisms and prognosis of patients with osteosarcoma.The pharmacogenomics of osteosarcoma.rs1760944 Polymorphism in the APE1 Region is Associated with Risk and Prognosis of Osteosarcoma in the Chinese Han Population.Meta-analysis showing that ERCC1 polymorphism is predictive of osteosarcoma prognosis.Genetic polymorphisms in ERCC1 and ERCC2 genes are associated with response to chemotherapy in osteosarcoma patients among Chinese population: a meta-analysis.ERCC1 rs3212986 A/C polymorphism is not associated with chemotherapy treatment outcomes in gastric cancer patients: evidence from 11 publications in Chinese populations.Association between the polymorphisms in XPG gene and gastric cancer susceptibility in Chinese populations: A PRISMA-compliant meta-analysis.Logistic regression analysis for the identification of the metastasis-associated signaling pathways of osteosarcoma.Haplotype analysis on relationship of ERCC2 and ERCC3 gene polymorphisms with osteosarcoma risk in Chinese young population.Excision repair cross-complementation group 1 protein expression predicts survival in patients with high-grade, non-metastatic osteosarcoma treated with neoadjuvant chemotherapy.Genetic polymorphisms in XPG could predict clinical outcome of platinum-based chemotherapy for advanced non-small cell lung cancer.Genetic susceptibility to bone and soft tissue sarcomas: a field synopsis and meta-analysis.XPG rs17655 G>C polymorphism associated with cancer risk: evidence from 60 studies.Association between common polymorphisms in ERCC gene and prognosis of osteosarcoma in patients treated with chemotherapy: a meta-analysis.The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients.The association of XRCC1 polymorphism with osteosarcoma risk, clinicopathologic features, and prognosis in a Chinese Han population
P2860
Q26782962-A5311546-8975-4387-9D16-27D6F20C0AEFQ28385328-733A453F-6F3E-43BE-AA9A-3CE92803491BQ28386513-DCE83E97-B3ED-49C5-9903-081CF1DCF5ADQ31170960-5645AF0C-9608-400C-8F9C-D31BA5967E46Q33975510-97BAF31D-BFA5-4834-B30B-3A60741BEFD2Q34265799-67F1AF01-FA83-4356-9FAF-2E77E5B8936BQ34983863-9431C32B-2210-4246-9B27-E726AA7A9DDFQ35167370-5662E778-35B8-4121-AF79-3DEACA0D3621Q35741160-C46804BD-6934-41C1-B9AF-DBD3EB68E778Q35764394-CDECE5AD-343D-496B-A03D-AEB8C7C72BEDQ37041218-DCE96CC0-606F-4ECA-A9DB-E128CD65770FQ37382606-2F175F8B-7262-4E81-8CD7-010E01589D57Q37641721-EC7710CE-3320-46EB-A9E3-81424A8DEE3AQ37719938-BA8F1E51-4CB4-483C-86E1-1138BEA02705Q38276429-CA130148-EF3F-476B-B96C-A14F68138B34Q38349935-7166977B-D00A-4093-8B14-649ECD8B37A0Q38396392-1CC71D80-70E6-4427-8B9A-2734EAD82E30Q38848413-420DC291-3813-493B-B03A-0B717B5C9440Q41516445-06AB6369-5C96-4E61-AAE2-D36E504CFBDEQ41883809-CD6E057E-2646-4684-A70A-E69234C3226FQ42090447-7855623C-27B1-4620-BBDC-F1D906F6B08AQ47105249-BB6013BE-E00D-4CE4-A66A-9A914A3715FEQ47151108-CC59560A-98E7-4244-96AB-056759F88648Q50068247-7E4E060F-F07F-4626-9AC9-3C8DCD07D38EQ53498004-2CD02C65-60A8-40E0-AE70-720A3DCD6575Q53641041-DA7C1519-F019-475E-BBED-60D5724F3919Q54218866-4F5CEC65-DBA4-4EBC-B613-98314F619C6FQ55004789-C6A14ADB-C70E-4BC6-8D6B-0FB6E142B12AQ55101935-3932DF99-4B91-40ED-93F2-97B89001EFD5Q55313372-469157A6-3151-4670-94CC-63BECABD4E03Q55455554-4F68EF39-F79E-4937-BB75-89CCBE075E4AQ59126239-C295799B-1A8D-4C83-8A22-0C5C89C6DB3A
P2860
Nucleotide excision repair gene variants and association with survival in osteosarcoma patients treated with neoadjuvant chemotherapy.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Nucleotide excision repair gen ...... with neoadjuvant chemotherapy.
@ast
Nucleotide excision repair gen ...... with neoadjuvant chemotherapy.
@en
type
label
Nucleotide excision repair gen ...... with neoadjuvant chemotherapy.
@ast
Nucleotide excision repair gen ...... with neoadjuvant chemotherapy.
@en
prefLabel
Nucleotide excision repair gen ...... with neoadjuvant chemotherapy.
@ast
Nucleotide excision repair gen ...... with neoadjuvant chemotherapy.
@en
P2093
P2860
P50
P356
P1476
Nucleotide excision repair gen ...... with neoadjuvant chemotherapy
@en
P2093
F Innocenti
M Alberghini
R Talamini
P2860
P2888
P304
P356
10.1038/TPJ.2011.33
P577
2011-08-09T00:00:00Z
P5875
P6179
1022739193